BACE1 and Alzheimer disease: We interpret our data that BACE1 inhibitor treatment at an early stage of β-amyloid deposition at least slows down progression of β-amyloid pathology, which raises realistic hope for delaying pathological progression in presymptomatic AD patients (illustrated in Fig. 5).